Seymour P, Jones SD, Levine HL. Technology Transfer of CMC Activities for MAb Manufacturing. BioProcess Int. 8(6) 2010: S46–S50.
Nixon L, Rudge S. Technology Transfer Challenges for In-Licensed Biopharmaceuticals. BioProcess Int. 8(10) 2010: 10–18.
Wei Z, et al. The Role of Higher-Order Structure in Defining Biopharmaceutical Quality. BioProcess Int. 9(4) 2011: 58–66.
Siemiatkoski J, et al. Glycosylation of Therapeutic Proteins. BioProcess Int. 9(6) 2011: 48–53.
Langer ES. Limited Analytical Technologies Are Inhibiting Industry Growth. BioProcess Int. 9(9) 2011: 18–23.
Mire-Sluis A, et al. Analysis and Immunogenic Potential of Aggregates and Particles. BioProcess Int. 9(10) 2011: 38–47.
Schilling BM, Abu-Absi S, Thompson P. Metabolic Process Engineering. BioProcess Int. 10(1) 2012: 42–49.
Whitford WG. Single-Use Technology Supports Follow-On Biologics. BioProcess Int. 10(5) 2012: S20–S31.
Kozlowski S, et al. QbD for Biologics. BioProcess Int. 10(8) 2012: 18–29.
Klinger C, et al. Enhancing Data Quality with a Partly Controllable System at Shake Flask Scale. BioProcess Int. 10(9) 2012: 68–72.
Mire-Sluis A, Kutza J, Frazier-Jessen M. Rapid Pharmaceutical Product Development. BioProcess Int. 10(11) 2012: 12–21.
Mire-Sluis A, et al. Drug Products for Biological Medicines. BioProcess Int. 11(4) 2013: 48–62.
We believe, however, that a solid rationale for the analytical part of the comparability exercise — based on impact assessment from the process changes — will be a major asset in the overall comparability process. That makes it worth every effort to develop the best comparability protocol.